Triangle Pharmaceuticals (VIRS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Triangle Pharmaceuticals (VIRS)

VIRS 40.03

0.0%

Oct 10 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: (no name provided) who wrote (10)	7/2/1997 11:10:00 PM
From: Thomas E. Wetherby	of 34

Kafka, VIRS management has such a good reputation that they could raise funds easily, and potentially without issuing more stock. Also, my source tells me that they are much closer to a filing than 1999. You mentioned some good examples of undervalued biotechs, I own some of those. I also own CYTO - 3 approved compounds, $250 million market cap. The biotech field is the most inefficient market out there. That is why you can make money on EITHER side of the trades. You may ultimately be right about the eventual dilution of VIRS, but for some reason, Wallstreet tends to like companies that concentrate on AIDS. I think this stock could run into the $30's before pulling back a large amount. Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next